May & Baker Introduces Malact, New Malaria Medicine

Nigeria’s leading pharmaceutical manufacturer, May & Baker Nigeria Plc has introduced a new anti-malarial medicine that promises to revolutionize malaria disease treatment in the country.

The new drug, named Malact is dihydroarteminsin-piperaquine combination-based formulation which ensures fast relief from malaria and guarantees better post treatment protection.

With  increasing  resistance  to  older  drugs,  the  World  Health  Organisation  (WHO)  years  back jettisoned  Chloroquine and  recommended  Artermisinin based  Combination  Therapies  (ACTs)  as first  line drug  for the  treatment of uncomplicated malaria.

However, most ACTs have since then shown    limitations including resistance to treatment. But dihydroarteminsin-piperaquine combination, the  newer artemisinin-based combination  therapy  has  shown excellent efficacy  in multiple trials and is considered the  most promising drug  currently  available  for the treatment of uncomplicated malaria.

The combination has a reliable efficacy which guarantees patient faster relief compared to other ACTs currently available in the market.  It also has better post treatment protection because of the piperaquine content that makes it possible for patients not to experience relapse for at least six weeks.

 

Check our Latest products!

 

Malact, the new product from May & Baker, therefore prevents malaria for up to six weeks and prevents recrudescence of malaria. Other advantages of Malact include convenient dosing because it is taken once a day and this reduces the chances of dosage non-compliance.It does not  require to be taken with fatty meals by the patient  before it can be absorbed.

At a media launch of the new anti-malaria product in Lagos, Mr Nnamdi  Okafor, Managing Director/CEO of May & Baker said the introduction of Malact is part of the company’s effort at  continually  confronting  the  malarial  scourge  by  providing  effective  and  affordable medicines for treatment of the disease.

He stated further that Malact is the latest and most effective arsenal in the toolbox for fight against malaria.He said the goal of May & Baker is to continue to be the one-stop-shop for quality antimalarials.

L-R: Pharm. Obinna Emeribe, head of marketing; Pharm. Chukutem Chukuka, executive director, Pharma Sales & Marketing; Pharm Nnamdi Okafor, managing director/CEO and Pharm Yetunde Adigun, head, Pharma Plant Operations, all of May & Baker Nigeria Plc at the media launch of Malact tablets, the company’s new anti.-malarial medicine in Lagos recently.

 

Mr Chukutem Chukuka, executive director, Pharma Sales& Marketing of May & Baker in his remarks said “Malact has a reliable efficacy which guarantees patient faster relief compared to other   Acts currently available in the market.

“It also has better posttreatment protection because of the piperaquine content that makes it possible for patients not to experience relapse for at least six weeks.Malact therefore prevents malaria for up to six weeks and prevents recrudescence of malaria”.

May & Baker Nigeria Plc remains a key player in the anti-malarial market in Nigeria. It was the first company to introduce an antimalarial drug to Nigerians with its Nivaquine brand of chloroquine  sulphate decades ago.

When the WHO discountenanced chloroquine as first line drug for the treatment of malaria, and recommended the ACTs, the company was one of  the  first  pharmaceutical manufacturers in Nigeria to locally produce  ACTs with the introduction of  its  artemisinin  combination  therapy  (ACT) antimalarial drug “Artelum” which is a brand of artemether/lumefantrine in April 2009.

 

Check our bestsellers!

 

According to the World Health organization, Malaria remains a  major global health challenge with over 200 million cases annually in Africa.It is responsible for over100, 000 deaths in Nigeria    every year.

In addition  to  loss of life, malaria places an economic burden on African nations that is  estimated to be worth  over  $12 billion in direct cost and GDP loss annually.

The introduction of the more efficacious dihydroarteminsin-piperaquine  based  anti-malarial  drug  is  therefore  a  great  relief  that  promises  to  reduce malaria related mortality.

May & Baker is Nigeria’s first pharmaceutical company with over 76 years’ experience of doing business in the country. It was among the few WHO-cGMP production facilities in Nigeria that  was  certified  by  the  World  Health  Organisation  in  2014.  Its vision is to become a leading healthcare brand in sub -Saharan Africa.

Leave a Reply

Your email address will not be published. Required fields are marked *

Call Now Button
Like Us On Facebook